Glucocorticoid-centered drug spectrum of non-jaw osteonecrosis, a FAERS pharmacovigilance study with independent validation in Canada Vigilance and JADER
Objective To distinguish jaw misclassification and litigation-related reporting from non-jaw osteonecrosis signals and define their reproducible spectrum. Methods We analyzed 20,690,895 deduplicated Food and Drug Administration Adverse Event Reporting System (FAERS) reports (2004Q1–2026Q2), using report-level adjudicat...